Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

HemaSure Inc.

(HMSR)

Josephthal's Berger repeated a "buy" on HMSR

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE